Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Study of MIRCERA for the Intrapetient Variability of Hemoglobin Levels in Patients With Chronic Renal Anemia (RIVAL)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Hoffmann-La Roche
ClinicalTrials.gov Identifier:
NCT01356589
First received: May 18, 2011
Last updated: November 23, 2015
Last verified: November 2015
  Purpose
This retrospective observational study will assess the incidence of hemoglobin cycling in chronic kidney disease (stage 3, 4, and 5) patients with renal anemia treated with Mircera (methoxy polyethylene glycol-epoetin beta). Data will be collected from each patient from a 9-month treatment period.

Condition
Anemia

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Retrospective Study on Intrapatient VAriabiLity of the Hemoglobin Levels in Anemic CKD Patients in Predialysis (Stage 3-4) and Dialysis (Stage 5) Treated With MIRCERA® (RIVAL Study)

Resource links provided by NLM:


Further study details as provided by Hoffmann-La Roche:

Primary Outcome Measures:
  • Percentage of Participants With at Least One Hemoglobin Cycling [ Time Frame: 9 months ] [ Designated as safety issue: No ]
    Hemoglobin cycling was defined as 1 or more cycles of oscillation in hemoglobin with an amplitude of greater than or equal to (>=) 1.5 gram per deciliter (g/dL) and a duration >=8 weeks.


Secondary Outcome Measures:
  • Number of Full Hemoglobin Cycles Per Participant [ Time Frame: 9 months ] [ Designated as safety issue: No ]
    Hemoglobin cycling was defined as 1 or more cycles of oscillation in hemoglobin with an amplitude of >=1.5 g/dL and a duration >=8 weeks.

  • Percentage of Participants With Type 2 Diabetes Who Experienced at Least 1 Hemoglobin Cycling [ Time Frame: 9 months ] [ Designated as safety issue: No ]
    Hemoglobin cycling was defined as 1 or more cycles of oscillation in hemoglobin with an amplitude of >=1.5 g/dL and a duration >=8 weeks.


Enrollment: 1288
Study Start Date: September 2010
Study Completion Date: July 2012
Primary Completion Date: July 2012 (Final data collection date for primary outcome measure)

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Chronic kidney disease patients with anemia treated with Mircera
Criteria

Inclusion Criteria:

  • Adult patients, >/= 18 years of age
  • Chronic kidney disease in predialysis (stage 3 and 4) and dialysis
  • Renal anemia treated with Mircera according to label for at least 9 months before date of signed informed consent

Exclusion Criteria:

  • Participation in an interventional clinical trial within the retrospective observation period
  • Contraindications to Mircera administration as per label or judged by the investigator
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01356589

Locations
Greece
Arta, Greece, 47100
Athens, Greece, 11362
Athens, Greece, 11521
Athens, Greece, 11526
Athens, Greece, 11527
Athens, Greece, 11528
Athens, Greece, 12351
Athens, Greece, 124 61
Athens, Greece, 15562
Athen, Greece, 14233
Daphni-athens, Greece, 17237
Drama, Greece, 66100
Egaleo, Greece, 12244
Heraklion, Greece, 71110
Katerini, Greece
Lamia, Greece, 35100
Larissa, Greece, 41 110
Larissa, Greece, 41335
Leivadia, Greece, 32100
Leykada, Greece, 31100
Patra, Greece, 26225
Patra, Greece, 26443
Piraeus, Greece, 18536
Polygyros, Greece, 63100
Rhodes, Greece, 85100
Serres, Greece
Thessaloniki, Greece, 54636
Thessaloniki, Greece, 54643
Thessaloniki, Greece, 56403
Thessaloniki, Greece, 57500
Volos, Greece, 38221
Volos, Greece, 38222
Sponsors and Collaborators
Hoffmann-La Roche
Investigators
Study Director: Clinical Trials Hoffmann-La Roche
  More Information

Responsible Party: Hoffmann-La Roche
ClinicalTrials.gov Identifier: NCT01356589     History of Changes
Other Study ID Numbers: ML25289 
Study First Received: May 18, 2011
Results First Received: November 23, 2015
Last Updated: November 23, 2015
Health Authority: Greece: National Organization of Medicines

Additional relevant MeSH terms:
Anemia
Hematologic Diseases

ClinicalTrials.gov processed this record on September 29, 2016